SCHEMBL22119474

SCHEMBL22119474

CCOC(=O)CCN(C#N)c1cccc(C2CCN(C(=O)OC(C)(C)C)CC2)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 1/20 0.43
POLB P06746 1/20 0.43
MAPT P10636 2/20 0.41
GPR119 Q8TDV5 4/20 0.41
MEN1 O00255 3/20 0.40
KMT2A Q03164 3/20 0.40
NAMPT P43490 1/20 0.40
LMNA P02545 2/20 0.40
THRB P10828 2/20 0.40
STS P08842 1/20 0.39
ALDH1A1 P00352 1/20 0.39
GAA P10253 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
NOTCH1 P46531 1/20 0.39
KDM4E B2RXH2 1/20 0.39
ALOX12 P18054 1/20 0.39
JAK2 O60674 1/20 0.38
JAK3 P52333 1/20 0.38
PTK2 Q05397 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30086984 1.00 TP53 (0.43) TP53POLBMAPTGPR119MEN1
SCHEMBL22119510 0.89 GPR119 (0.45) TP53POLBGPR119MEN1KMT2A
SCHEMBL22119622 0.88 SMN1; SMN2 (0.39) TP53MAPTMEN1KMT2ALMNA
SCHEMBL30087126 0.86 TP53 (0.43) TP53POLBMAPTGPR119MEN1
SCHEMBL22119549 0.86 TP53 (0.43) TP53POLBMAPTGPR119MEN1
SCHEMBL24480436 0.79 GPR119 (0.59) GPR119
SCHEMBL30313413 0.78 ALOX12 (0.49) TP53POLBMAPTGPR119NAMPT
SCHEMBL22119497 0.78 ALOX12 (0.49) TP53POLBMAPTGPR119NAMPT
SCHEMBL22119599 0.78 MAPT (0.47) MAPTGPR119MEN1KMT2ANAMPT
SCHEMBL31630911 0.76 NAMPT (0.42) MAPTGPR119NAMPTTHRBKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12559492-B2 BRAF degraders C4 THERAPEUTICS, INC. (US) 2026-02-24 US disclosed
US-20260015338-A1 TARGETED PROTEIN DEGRADATION C4 THERAPEUTICS, INC. (US) 2026-01-15 US disclosed
US-12454521-B2 Targeted protein degradation C4 THERAPEUTICS, INC. 2025-10-28 US disclosed
US-20230145336-A1 BRAF DEGRADERS C4 THERAPEUTICS, INC. (US) 2023-05-11 US disclosed
EP-4168407-A1 BRAF DEGRADERS C4 Therapeutics, Inc. (US) 2023-04-26 EP disclosed
US-20220372016-A1 TARGETED PROTEIN DEGRADATION C4 THERAPEUTICS, INC. (US) 2022-11-24 US disclosed
WO-2021255212-A1 BRAF DEGRADERS F. HOFFMANN-LA ROCHE AG (CH) 2021-12-23 WO disclosed
EP-3897631-A1 TARGETED PROTEIN DEGRADATION C4 Therapeutics, Inc. (US) 2021-10-27 EP disclosed
CN-113453679-A Targeted protein degradation C4医药公司 2021-09-28 CN disclosed
WO-2020132561-A1 TARGETED PROTEIN DEGRADATION C4 THERAPEUTICS, INC. (US) 2020-06-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260015338-A1 TARGETED PROTEIN DEGRADATION PSMC3, PSMA6, ADRM1 TP53 557/4885POLB 4498/4885MAPT 2902/4885
US-12559492-B2 BRAF degraders BRAF, NRAS, HRAS TP53 69/4885POLB 791/4885MAPT 4613/4885
US-20220372016-A1 TARGETED PROTEIN DEGRADATION STUB1, MDM2, UBE3A TP53 180/4885POLB 3295/4885MAPT 288/4885
US-12454521-B2 Targeted protein degradation STUB1, MDM2, UBE3A TP53 180/4885POLB 3295/4885MAPT 288/4885
US-20230145336-A1 BRAF DEGRADERS BRAF, NRAS, RAF1 TP53 7/4885POLB 698/4885MAPT 2440/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.